Relaro Medical Trials: Company Profile
Background
Overview
Relaro Medical Trials is a dedicated clinical research organization based in Dallas, Texas, specializing in Phase II through IV clinical trials. Established in 2013, the company focuses on advancing medical knowledge and improving patient care through rigorous and ethical research practices. With a team boasting over 80 years of combined experience, Relaro emphasizes a patient-centered approach, ensuring that each individual feels informed, supported, and respected throughout their clinical trial journey.
Mission and Vision
The mission of Relaro Medical Trials is to empower the community through education and access to clinical trials. By collaborating closely with patients and healthcare providers, the organization upholds the highest standards of safety, quality, and care, aiming to advance science while keeping people at the heart of everything they do.
Primary Area of Focus
Relaro specializes in clinical trials across various therapeutic areas, with a strong emphasis on psychiatry and neurodevelopmental disorders. Their research encompasses conditions such as depression, anxiety, bipolar disorder, schizophrenia, autism spectrum disorder, Alzheimer's disease, and Tourette's disorder. This focus underscores their commitment to addressing complex mental health challenges through innovative research.
Industry Significance
Operating within the clinical research services industry, Relaro Medical Trials contributes significantly to the development of new treatments and therapies. By conducting high-quality, patient-centered research, the organization plays a crucial role in advancing medical knowledge and improving patient outcomes, particularly in the realm of mental health.
Key Strategic Focus
Core Objectives
Relaro's strategic focus centers on delivering high-quality clinical research services that prioritize patient safety and ethical standards. The organization aims to foster strong partnerships with sponsors and healthcare providers, ensuring efficient study execution and meaningful contributions to medical science.
Specific Areas of Specialization
The company specializes in conducting clinical trials in psychiatry and neurodevelopmental disorders, addressing a range of conditions including:
- Depression
- Anxiety
- Bipolar Disorder
- Schizophrenia
- Autism Spectrum Disorder
- Alzheimer's Disease
- Tourette's Disorder
This specialization reflects their dedication to advancing treatments in these critical areas of mental health.
Key Technologies Utilized
While specific technological platforms are not detailed, Relaro emphasizes the importance of data accuracy and transparency in their research processes. This suggests the adoption of advanced technologies for clinical trial management and data collection to uphold high standards of quality and compliance.
Primary Markets or Conditions Targeted
Relaro primarily targets the mental health sector, focusing on conditions such as depression, anxiety, bipolar disorder, schizophrenia, autism spectrum disorder, Alzheimer's disease, and Tourette's disorder. By concentrating on these areas, the organization aims to address significant unmet needs in mental health care through innovative research.
Financials and Funding
Funding History
Specific details regarding Relaro Medical Trials' funding history are not publicly disclosed. However, the company operates within a revenue range of $10 million to $25 million, indicating a solid financial foundation and potential for growth.
Total Funds Raised
The exact total funds raised by Relaro Medical Trials are not specified.
Recent Funding Rounds
Information about recent funding rounds is not publicly available.
Notable Investors
Details about notable investors in Relaro Medical Trials are not disclosed.
Intended Utilization of Capital
While specific plans for capital utilization are not detailed, the company's focus on expanding its clinical trial capabilities and enhancing patient care suggests that funds are likely allocated towards research development, infrastructure improvements, and community outreach initiatives.
Pipeline Development
Key Pipeline Candidates
Relaro Medical Trials is involved in various clinical studies targeting conditions such as:
- Adolescent and Adult ADHD
- Social Anxiety
- General Anxiety
- Autism
- Bipolar Disorder
- Bipolar Depression
- Depression/Treatment Resistant
- Diabetes
- Dry Eye
- OCD
- Genomic Testing
- Glaucoma
- Smoking Cessation
- Osteoarthritis
- PTSD
- Schizophrenia
- Tourette Syndrome
- Weight Loss
- Migraine
- Insomnia
These studies are in various stages of development, aiming to address a broad spectrum of health conditions.
Stages of Clinical Trials or Product Development
Relaro conducts Phase II through IV clinical trials, focusing on evaluating the safety and efficacy of treatments in larger patient populations. This progression allows for comprehensive assessment of therapeutic interventions before they become widely available.
Target Conditions
The company's clinical trials target a range of conditions, primarily in the psychiatric and neurodevelopmental domains, including depression, anxiety, bipolar disorder, schizophrenia, autism spectrum disorder, Alzheimer's disease, and Tourette's disorder.
Relevant Timelines for Anticipated Milestones
Specific timelines for anticipated milestones in Relaro's clinical trials are not publicly disclosed. However, the company's ongoing recruitment for various studies indicates active progress in their research initiatives.
Technological Platform and Innovation
Proprietary Technologies
While specific proprietary technologies are not detailed, Relaro emphasizes the importance of data accuracy and transparency in their research processes. This suggests the adoption of advanced technologies for clinical trial management and data collection to uphold high standards of quality and compliance.
Significant Scientific Methods
Relaro employs a multidisciplinary, patient-centered approach in their clinical trials, ensuring safety, comfort, and clarity throughout the trial process. This methodology reflects their commitment to ethical research practices and patient well-being.
AI-Driven Capabilities
Specific details regarding AI-driven capabilities are not provided.
Leadership Team
Key Executive Profiles
- Renee Unger-LaRoque: Founder and Site Director with over 28 years in the industry, overseeing clinical operations and ensuring compliance.
- Dr. Eric Williams, M.D.: Board-certified psychiatrist with over 15 years of experience, serving as Principal Investigator and contributing to mental health clinical trials.
- Dr. Bradley Musser, M.D.: Principal Investigator with extensive experience in psychiatry, involved in numerous clinical trials.
- Dr. Thomas Grugle, M.D.: Principal Investigator with a background in general medicine and psychiatry, contributing to over 50 clinical trials.
- Dr. Vipin Kuriachan, M.D.: Principal Investigator specializing in ophthalmology, leading the Kuriachan Eye Institute in Irving, Texas.
- Dr. Seema Gupta, M.D.: Principal Investigator with a focus on child psychiatry, involved in various psychiatric clinical trials.
- Dr. Kinjal Gadhiya, M.D.: Sub-Investigator specializing in internal medicine and obesity medicine, serving as an Investigator at Relaro since 2024.
- Claudia Harris: Clinical
